Alnylam Q3 net product revenue $232M (+39% YoY); AMVUTTRA Q3 sales $25M; reiterates FY product revenue guide $870-930M

ALNYLAM PHARMACEUTICALS, INC.

2022-Q3 EPS reported -$7.62 revenue$702,383,000

Q3 2022 GAAP net loss $405.9M ($3.32/sh) vs $204.5M ($1.72/sh) YoY; non-GAAP net loss $193.4M ($1.58/sh) vs $189.8M ($1.59/sh).
Combined net product revenue $232M: TTR $170M (ONPATTRO $145M, AMVUTTRA $25M), GIVLAARI $46M, OXLUMO $16M.
Reiterated FY 2022 product revenue guidance $870-$930M; lowered collaboration/royalty guidance to $100-$150M from $175-$225M.
AMVUTTRA U.S. launch strong: $25M net rev in first full quarter, 475 Start Forms, 46% new patients, 54% switches from ONPATTRO.
Positive APOLLO-B Phase 3 results for patisiran in ATTR cardiomyopathy; sNDA submission on track for late 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.